Purpose: We recently developed a new instrument called 'diffuse in vivo flow cytometry' (DiFC) for enumeration of rare fluorescently-labeled circulating tumor cells (CTCs) in small animals without drawing blood samples. Until now, we have used cell lines that express fluorescent proteins, or were pre-labeled with a fluorescent dye ex-vivo. In this work, we investigated the use of two folate receptor (FR)-targeted fluorescence molecular probes for in vivo labeling of FR+ CTCs for DiFC.
Introduction
Cancer metastasis is a multi-step process, by which tumor cells colonize distant organs and tissues. The circulatory system is one of the most common pathways, wherein tumor cells intravasate into the peripheral blood, circulate, and form metastases at secondary sites [1] [2] [3] . Circulating tumor cells (CTCs) in the bloodstream are therefore of great interest in cancer research. Numerous studies have demonstrated that CTC numbers correlate with overall survival, disease progression, and response to treatment for many cancers [4] [5] [6] [7] [8] [9] . CTCs are extremely rare; fewer than 1 CTC per mL of peripheral blood is considered prognostically negative [10] .
Normally, CTCs are studied using 'liquid biopsy', where relatively small blood samples are drawn from the patient or small animal (in the case of pre-clinical research), are purified, enriched and further analyzed [11] [12] . Although these are widely used in biomedical research, they are far from optimal for a number of reasons. In particular, small blood samples provide poor statistical sampling of the circulating blood volume [13] [14] [15] , blood is known to degrade rapidly after removal from the body [16] , and enrichment can cause cell loss or dissolution [17] [18] . Moreover, in the case of small animal studies CTCs may be so rare that it is necessary to draw and analyze the entire blood volume, which requires euthanizing the animal [19] . This precludes longitudinal study of individual animals over time.
These limitations have driven the development of optical methods for enumerating circulating cells without having to draw blood samples, collectively termed 'in vivo flow cytometry' (IVFC) [20] [21] [22] [23] . IVFC typically uses specialized confocal microscopy [24] [25] [26] [27] or photoacoustic [28] [29] [30] instrumentation to detect circulating cells, for example in a small blood vessel in the ear of a mouse. Our group recently developed 'diffuse in vivo flow cytometry" (DiFC) [31] [32] [33] [34] , a new technique for counting rare fluorescently-labeled CTCs with highly scattered light. This allows sampling of large circulating blood volumes (compared to a microscope), and therefore detection of less abundant cells. For example, we recently [33] used DiFC to monitor dissemination of multiple myeloma cells in a xenograft model, and showed that we could noninvasively detect fewer than 1 CTC per mL of blood. In addition to detection sensitivity, a major advantage of DiFC is that it works in bulk, optically diffusive tissue such as the mouse leg or tail (as opposed to the thin ear of a mouse as in microscopy) so in principle could be used in larger limbs and species. However, until now we have only used DiFC with CTCs that express green fluorescent proteins (GFP) or by labeling cells ex-vivo with membrane or cytosol dyes. This presently limits the use of DiFC to the study of mouse xenograft models using cultured immortalized cell lines [32] [33] .
Use of a targeted fluorescent molecular probe that could label CTCs while in circulation would therefore greatly expand the utility of DiFC. In this work, we studied two folate receptor (FR) alpha (a) targeted molecular probes for DiFC for the first time. FR is widely used as a therapeutic and diagnostic target for cancer, since it is often over-expressed in many epithelial cancers [35] [36] [37] [38] , including ovarian [39] [40] [41] [42] , breast [43] [44] , and non-small cell lung carcinomas [45] [46] . It also is purported to have very low expression in normal tissues [35] [36] [37] . Cell surface-receptor targeted molecular contrast agents have already been used for microscopy-IVFC previously [22, 47] including for FR+ cells [24, 48] . However, a major question was whether CTCs could be labeled in vivo with sufficient specificity and brightness for detection with DiFC. DiFC uses diffuse light and is more therefore susceptible to scatter and attenuation of biological tissue (compared to microscopy) [49] , and as such may have higher fluorescence labeling requirements [22, 32] .
Specifically, we used EC-17 and Cy5-PEG-FR FRa-fluorescent probes. EC-17 is a small-molecule FITC based probe that was originally developed for fluorescence guided surgery (FGS) and has been shown to have high-affinity for FR+ CTCs previously [48] . Moreover, EC-17 and its NIR analog OTL-38 have both been used in FGS clinical trials [39, 50] , leading to the exciting possibility of using DiFC in humans in the future. Cy5-PEG-FR is a larger molecular weight probe, but has the advantage of having red excitation and emission wavelengths, which in principle is favorable for DiFC because of reduced optical attenuation of red light in biological tissue [49] . We tested these probes with two FR+ human cancer cell lines. As we show, EC-17 has very sensitivity and specificity for FR+ CTCs and labeled CTCs were detectable in mice in vivo with DiFC. In contrast, Cy5-PEG-FR demonstrated significant non-specific uptake in blood. Overall, this work demonstrates the feasibility of using targeted molecular probes for DiFC for the first time, which could greatly extend its utility in CTC research. 2. Materials and Methods.
Diffuse In Vivo Flow Cytometry
The DiFC instrument setup is shown in figs. 1a, b. The design and signal processing algorithms were described in detail by us previously [32] [33] . Briefly, DiFC works on the principle of laser-induced fluorescence. The DiFC fiber probes (red arrows, fig. 1c,d ) have integrated optical filters and lenses that allow detection of the weak fluorescence signal from individual moving cells in the bloodstream [34] . When placed over a major blood vessel, for example in the tail or leg ( fig. 1c ) of a mouse, transient fluorescence peaks are detected and counted We showed previously that the ventral caudal artery in a mouse tail carried hundreds of µL of blood per minute [32] , allowing us to detect and count very rare circulating cells [33] . 
Folate-Receptor (FR) Targeted Fluorescent Molecular Probes.
EC-17 is a small molecule FRa targeted probe (MW: 917 Da) which was developed in the lab of Prof. Low, and been extensively characterized previously [48, 51] . EC-17 is a conjugation of Fluorescein Isocyanate (FITC) to folic acid, which is the binding ligand of folate receptor. Previous work showed that EC-17 has excellent affinity for FR+ CTCs in blood compared to larger antibody-based probes [24, 48] . The EC-17 maximum excitation and emission wavelengths are 490 nm and 520 nm, respectively.
Cy5-PEG-FR is a larger (MW: 3500 Da) FRa-targeted probe (PG2-FAS5-2k; Nanocs Inc, New York, N). Cy5-PEG-FR has a 2 kDa PEG linker chain between the Cy5 and folate groups, which maintains its photostability and avoids Cy5 quenching, however as we show may contribute to non-specific uptake in blood. The maximum excitation and emission wavelengths of Cy5-PEG-FR are 647nm and 664nm, respectively.
Cell lines
KB are FR+ HeLa-derived human cervical cancer line and were purchased from ATCC (CCL-17; ATCC, Manassas, VA). L1210A is an FR+ human leukemia cancer line that was previously modified to express folate receptors (Purdue University, West Lafayette, IN). MM.1S multiple myeloma cells were used as an FR-control and were also purchased from ATCC (CRL-2974). All cell lines were cultured in RPMI 1640, folate deficient media (Gibco 27016-021; ThermoFisher Scientific, Waltham, MA).
Fluorescent Microspheres
We used fluorescence microspheres as a reference standard for evaluating the brightness of labeled cells.
"Dragon Green" (DG; DG06M, Bangs Laboratories, Fishers, IN) and "Flash Red" (FR; FR06M, Bangs) microspheres are sold in kits of 5 intensities, ranging from 1 (lowest) to 5 (highest). These serve as useful standards for evaluating cell labeling, and for comparing data between different instruments, for example between a flow cytometer (FC) and DiFC. Our previous work showed that cells with fluorescent labeling equal to or exceeding FR4 had high signal-to-noise ratios in vivo [32] . Likewise, blue fluorescence labeling exceeding DG3 were readily detectable with b-DiFC in SCID mice in vivo [33] .
Labeling of Cells with FR-Targeted Probes In Vitro
We first tested labeling of FR+ CTC with the FR-targeted probes in cells in culture in vitro. EC-17 was added at a concentration of 200 nM to suspensions of 10 6 cells/mL in 2% FBS in PBS in a 6-well plates.
Cells were incubated at 37 o C for 60 minutes, then washed twice with PBS, and resuspended at a concentration of 10 6 cells/mL. Cy5-PEG-FR was added at a concentration of 1.6 µM to suspensions of 0.5
x 10 6 cells/mL at 4 o C for 30 minutes. Following this, cells were washed twice and resuspended at a concentration of 10 6 cells/mL prior to testing with flow cytometry (FC) or DiFC.
Labeling of Cells in Whole Mouse Blood
We next tested labeling of FR+ CTCs in whole mouse blood. Blood was drawn from female nude (nu/nu) mice (Charles River Laboratory, Wilmington, MA), which were kept on folic-acid free diet (TD.00434;
Teklad Diet, UK) for at least 2 weeks prior to the study to minimize free folic acid in the blood. Drawn blood was stabilized and diluted 1:1 with 1000 units/ml Heparin (Sigma Aldrich, Natick, MA). 10 4 CTCs were added to 500 µL blood aliquots ("spiked") and then gently agitated for 30 seconds to ensure that samples were well mixed. 200 nM EC-17 or 1.6 µM Cy5-PEG-FR were added to the blood samples, and these were incubated for 60 minutes as above.
To test EC-17 labeling specificity, target (KB, L1210A or MM.1s) cells were first pre-labeled with Some samples were also co-incubated with 10 µM of free folic acid to introduce competitive binding. Blood suspensions were then analyzed using the blue (488 nm laser, 530 nm emission filter), and red (637 nm laser, 647 nm emission filter) channels of an Attune NXT flow cytometer (ThermoFisher).
Experiments were repeated at least in duplicate in each case.
DiFC Flow Phantom Experiments In Vitro
As an initial test of the detectability of EC-17 and Cy5-PEG-FR labeled cells with DiFC, we used a tissuesimulating flow phantom model ( fig. 1d ), as we have in our previous work [32] . Briefly, the flow phantom was a block of optically diffusing high-density polyethylene (HDPE) with similar scatter and absorption properties of biological tissue. A strand of microbore Tygon tubing (TGY-010-C, Small Parts, Inc., Seattle, Washington) was embedded in the phantom block at a depth of 0.75 mm. The tubing was connected to a syringe pump (70-2209, Harvard Apparatus, Holliston, Massachusetts). We prepared suspensions of 10 3
per mL cells suspension of EC-17 and Cy5-PEG-FR labeled L1210A cells per mL, labeled as described in section 2.4. Cell suspensions were run through the phantom at a rate of 50 µL/s. We also tested 10 3 spheres/mL suspensions of DG3 and FR4 fluorescence reference microspheres at concentrations of 10 3 spheres/mL as a comparison.
DiFC Mouse Experiments In Vivo
All mice were handled in accordance with Northeastern University's Institutional Animal Care and Use Committee (IACUC) policies on animal care. Animal experiments were carried out under Northeastern University IACUC protocol #15-0728R. All experiments and methods were performed with approval from, and in accordance with relevant guidelines and regulations of Northeastern University IACUC.
L1210A leukemia cells were used in these experiments, since they are known to circulate for extended periods of time when intravenously injected in mice [14] . We first labeled L1210A cells with EC-17 in vitro as above. Second, we also performed proof-of-principle testing of EC-17 labeling of FR+ CTCs while in circulation (which we subsequently refer to as "in vivo labeling"). Specifically we injected 10 6 L1210A cells i.v. via the tail vein. 5 minutes later, we administered 25ug of EC-17 probe by i.v. injection. We performed DiFC on the mouse hindleg, beginning approximately 40 minutes after the probe injection (45 minutes after cell injection).
Results

Labeling of FR+ CTCs in Cells In Vitro
We first tested labeling of FR+ CTCs with EC-17 in cell culture in vitro. Figure 2a shows that FR+ CTCs We next tested if EC-17-labeled FR+ CTCs were sufficiently brightly-labeled to be detectable with b-DiFC in a tissue-simulating optical flow phantom ( fig. 1d ) [33] . 
Labeling of FR+ Cells in Whole Mouse Blood.
We next tested labeling of FR+ CTCs in whole mouse blood with EC-17 and Cy5-PEG-FR probes. Blood is a complex suspension of billions of cells per mL, and therefore presents a more realistic model of in vivo labeling where non-specific cell uptake and competitive binding may occur.
Figure 4: Labeling of CTCs with EC-17 in whole mouse blood in vitro. (a) Red and blue autofluorescence of blood (only). (b) Non-specific uptake of EC-17 by blood cells was minimal, whereas there was substantial specific labeling of FR+ (c) L1210A and (d) KB cells. (e) addition of free-folic acid blocked binding of EC-17 to L1210 cells in blood. (f) FR-MM.1s cells showed negligible EC-17 uptake. (g) Summary of blue-fluorescence FC measurements for all experiments performed is shown.
The results are summarized in figure 4 . The blue (horizontal axis) and red (vertical axis) autofluorescence of whole mouse blood is shown in fig. 4a . Addition of EC-17 probe to the blood (only) showed a small amount non-specific uptake of EC-17 ( fig. 4b, blue horizontal axis), most likely by macrophages which is consistent with previously reported work [48] . As shown in fig. 4c , we added CTFR-prelabeled L1210A cells to blood, and then EC-17 probe. More than 90% of L1210A CTCs were well labeled with EC-17, and the average brightness of labeled cells was above non-specific background levels (shown in fig. 4b ). As shown in fig. 4d FR+ KB cells were also brightly labeled with EC-17. Furthermore, addition of free folic fig. 4e) . In addition, FR-MM.1s cells showed little binding of the EC-17 probe (fig 4f) .
The distributions of EC-17 (blue) fluorescence for all the experiments performed in this study are summarized in fig. 4g . When considering blue-fluorescence alone, these data show a clear separation between non-specific uptake of blood cells and FR-CTCs with EC-17 (lines 2 and 3) compared to FR+ CTCs labeling by EC- 17 (lines 8 and 9 ). In addition, the maximum fluorescence labeling of CTCs in the blood was 2.9 times lower than labeling in simple PBS solution in vitro ( fig. 2g) , which is unsurprising given the relative complexity of blood versus PBS.
Using the same methodology, we tested Cy5-PEG-FR labeling of FR+ L1210A cells as summarized in figure 5 . Blood autofluorescence is shown in fig. 5a . Addition of the Cy5-PEG-FR probe to whole blood showed significant non-specific uptake as shown in fig. 5b (vertical axis, red channel). Cy5-PEG-FR probe labeling of blood samples spiked with CFSE-labeled L1210A cells yielded a significant double-labeled population (fig 5c) . However, the large non-specific uptake by blood cells (figs. 5b,c) in the same fluorescence intensity ranges meant that the target cell population would not be identifiable using only the red (Cy5) fluorescence as shown in fig. 5d , and therefore would be unsuitable for r-DiFC. 
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In summary, these in vitro blood labeling experiments demonstrated that the small-molecule EC-17 was the more promising probe for in vivo labeling of FR+ CTCs for DiFC.
In Vivo Detection of EC-17 labeled CTCs with DiFC
We next tested if FR+ CTCs that were well-labeled with EC-17 were detectable with DiFC in mice in vivo.
To test this, we pre-labeled L1210A cells with EC-17 in culture in vitro, and then injected these i.v. via the tail vein into nude mice. We performed b-DiFC on the mouse hind-leg, approximately above the large femoral blood vessel as in fig. 1c . Representative b-DiFC data is shown in figure 6. Fig. 6a shows b-DiFC from a non-injected control mouse. As shown, the background signal was quite stable, with a mean noise standard deviation (s) of 1.9 mV, and false-alarm rate (FAR) of 0.008 counts per minute, when a detection threshold of 6 times s was used (calculated for each mouse). Fig. 6b shows representative b-DiFC data from a mouse injected with pre-labeled L1210A cells. Labeled L1210A cells were clearly detectable with b-DiFC, with mean signal to noise ratio of 18 dB, although some individual detections exceeded 30 dB.
The mean count rate for all 3 mice tested was 0.8 cell counts per minute (48 counts per hour). Following DiFC scanning, we drew 1 mL of blood (terminal) from the mice and counted EC-17+ cells in the blood using fluorescence (blue channel) FC. On average we counted 13.2 ± 5.7 EC-17 labeled cells per mL in blood, where we defined "labeled" as exceeding the blue fluorescence intensity of DG3 microspheres. This relatively low number of cells in the blood was expected from the fact that blood was sampled approximately 100 minutes after injection of the cells, meaning that very few L1210A cells remained in circulation.
Using this cell concentration, we were able to estimate the DiFC blood sampling rate from the mouse leg (femoral artery) as follows: The DiFC count rate measured during the final 10 minutes of the scan (just before drawing blood) was 0.6 ± 0.3 counts per minute. Compared to the estimated number of L1210A cells in the blood (13.2 cells/mL), this implies that DiFC sampled approximately 0.6 counts min -1 / 13.2 cells mL -1 = 48 µL / minute of blood. This is lower than our previously reported flow speed in ventral caudal artery in the mouse tail [32] , which reflects the smaller size of the mouse femoral artery compared to the tail artery.
In Vivo Labeling of CTCs with EC-17 and Detection with DiFC
Direct in vivo labeling of FR+ CTCs while in is a more challenging problem, and based on our studies in mouse blood samples we anticipated that CTC labeling would be significantly less bright than in culture in vitro. To test this, we first injected a suspension of L1210A cells in mice. 5 minutes later, we injected EC-17 probe. After approximately 40 minutes (allowing time for the free EC-17 to clear from circulation), we performed b-DiFC on the mouse hind-leg as above. Representative data is shown in fig. 6c . As shown, we were able to detect a small number of cells in circulation, at an average count rate of 0.1 per minute.
The measured FAR and count rates for pre-labeled and in-vivo labeled cells are summarized in fig.   6d . The lower count rate for in vivo labeling (12.5% of pre-labeled) stems from two reasons. First we started DiFC scanning approximately 45 minutes after injection of cells (versus 10 minutes for pre-labeled cells), so that many of the injected cells likely already cleared from circulation. Second, uptake and labeling of EC-17 cells by L1210A cells while in circulation in vivo was likely significantly less efficient than solution.
With respect to the latter, the histogram of detected peak amplitudes (expressed in mV and dB) in vivo are summarized in fig. 6e . From these data, we can estimate (approximately) that the lower count rate for in vivo labeled cells could be explained by a reduction of 14-16 dB labeling brightness. This in turn suggests that cells labeled in vivo were approximately 5-to-6 times lower in fluorescence brightness (labeling) than cells that were pre-labeled in culture. This is a reasonable estimation, given that we observed a reduction in EC-17 labeling brightness by a factor of 2.9 when labeling in blood compared to in PBS (figure 4).
However, in aggregate these data demonstrate the feasibility of detecting CTCs in vivo by direct labeling with DiFC. Further implications and future steps to increase DiFC detection efficiency are discussed in more details below.
Discussion
We recently developed DiFC, a new technique for detecting and enumerating very rare fluorescentlylabeled circulating cells in the bloodstream in small animals. Until now, we have only used DiFC with cells that were "pre-labeled" before introduction into to the circulatory system, either by using cell lines genetically modified to express GFP or by labeling with a membrane or cytosol dye [32] [33] . While useful for many mouse models of cancer metastasis, this ultimately restricts the use of DiFC to cultured cell lines.
Therefore, we are interested in developing a receptor-based fluorescence labeling approach [47] , since this could greatly extend the preclinical utility of DiFC. In addition, because DiFC is inherently scalable to larger limbs and tissues in combination with FDA approved fluorescent probes, this could ultimately open the possibility of use of DiFC in humans for enumeration of CTCs.
To achieve this, there were two main considerations for use of a FR targeted molecular probes.
First, because blood is a complex mixture of many cell types the specificity and affinity for CTCs is critical.
As shown in figures 2 and 3, both EC-17 and Cy5-PEG-FR demonstrated extremely bright labeling in simple cell culture. However, in whole blood EC-17 performed significantly better than Cy5-PEG-FR, exhibiting was substantial separation in fluorescence labeling between FR+ CTCs and non-target cells ( figure 4) . This is consistent with previously published work with small molecular weight folate receptor targeted probes [48] . In contrast, the larger molecular weight Cy5-PEG-FR experienced significant nonspecific uptake in whole blood, likely by macrophages (figure 4) making it infeasible as an in vivo injectable molecular probe based on red-fluorescence alone.
The second major consideration was the general issue of the detectability of fluorescence from a single-cell. As noted, DiFC works with diffuse photons in relatively deeply-seated (1-2 mm depth) large blood vessels. We previously estimated that DiFC requires labeling with approximately 10 5 fluorescent molecules per cell for detectability [22] . It is well established that blue light experiences significantly more attenuation and scatter in biological tissue than red light in general, and in the specific case of DiFC (1-2 mm deep) can result in loss of approximately 50% sensitivity [33] . As such, it was unclear if EC-17 receptor-labeled CTCs would be sufficiently bright for detection with DiFC, as opposed to GFP-expressing CTCs which are generally very bright [22] .
The mouse experiments performed here demonstrated that cells that were labeled in culture prior to injection were readily detectable by DiFC with high SNRs. When the cells and probe were injected separately ("in vivo labeling"), we were able to detect several cells, but at a count rate of approximately 12.5% compared to pre-labeled cells. This implies that many cells were labeled below the sensitivity level of DiFC, and as we noted could be explained by a reduction in EC-17 uptake by a factor of 5-6 compared to in cell culture. We tried doubling the injected quantity of EC-17 (to 50 µg) but this simply increased the background signal unacceptably, and yielded no appreciable increase in peak SNR.
Nevertheless, in combination these data provided proof-of-concept for use of FR targeted probes for DiFC. We next plan to pursue DiFC instrument and signal processing improvements to improve detection sensitivity. Moreover, a red or NIR small molecular version of EC-17 including OTL-38 may improve detectability due to more favorable tissue optics compared to blue light. This work also opens the use of DiFC to other molecular probes that target alternate cell-surface receptors. Finally, because a number of FR receptor targeted probes are in advanced clinical trials, this opens the exciting possibility of ultimately using DiFC in humans to enumerate CTCs directly in the bloodstream.
